149 related articles for article (PubMed ID: 37952082)
21. Hyperfractionated radiotherapy for T2N0 glottic carcinoma: a retrospective analysis at 10 years follow-up in a series of 60 consecutive patients.
Bignardi M; Antognoni P; Sanguineti G; Magli A; Molteni M; Merlotti A; Richetti A; Tordiglione M; Conte L; Magno L
Tumori; 2004; 90(3):317-23. PubMed ID: 15315312
[TBL] [Abstract][Full Text] [Related]
22. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
[TBL] [Abstract][Full Text] [Related]
23. Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors.
Sakata K; Someya M; Hori M; Nakata K; Takagi M; Hareyama M
Strahlenther Onkol; 2008 Jul; 184(7):364-9. PubMed ID: 19016035
[TBL] [Abstract][Full Text] [Related]
24. Radiotherapy Versus Cordectomy in the Management of Early Glottic Cancer.
Chung SY; Kim KH; Keum KC; Koh YW; Kim SH; Choi EC; Lee CG
Cancer Res Treat; 2018 Jan; 50(1):156-163. PubMed ID: 28301924
[TBL] [Abstract][Full Text] [Related]
25. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
[TBL] [Abstract][Full Text] [Related]
26. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation.
Spector JG; Sessions DG; Chao KS; Haughey BH; Hanson JM; Simpson JR; Perez CA
Head Neck; 1999 Dec; 21(8):707-17. PubMed ID: 10562683
[TBL] [Abstract][Full Text] [Related]
27. Significance of pretreatment hemoglobin level in patients with T1 glottic cancer.
Canaday DJ; Regine WF; Mohiuddin M; Zollinger W; Machtay M; Lee J; Schultz D; Rudoltz MS
Radiat Oncol Investig; 1999; 7(1):42-8. PubMed ID: 10030623
[TBL] [Abstract][Full Text] [Related]
28. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
[TBL] [Abstract][Full Text] [Related]
29. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
[TBL] [Abstract][Full Text] [Related]
30. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas.
Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Hirakawa A; Naganawa S
Asian Pac J Cancer Prev; 2018 May; 19(5):1195-1199. PubMed ID: 29801401
[TBL] [Abstract][Full Text] [Related]
31. Radiation therapy in early glottic carcinoma: uni- and multivariate analysis of prognostic factors affecting local control.
Sakata K; Aoki Y; Karasawa K; Hasezawa K; Muta N; Nakagawa K; Terahara A; Onogi Y; Sasaki Y; Akanuma A
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1059-64. PubMed ID: 7961012
[TBL] [Abstract][Full Text] [Related]
32. Patterns of failure for early-stage glottic carcinoma: 10 years' experience in conformal radiotherapy era.
Sert F; Kaya I; Ozturk K; Esassolak M
J Cancer Res Ther; 2019; 15(3):576-581. PubMed ID: 31169223
[TBL] [Abstract][Full Text] [Related]
33. Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience.
Gowda RV; Henk JM; Mais KL; Sykes AJ; Swindell R; Slevin NJ
Radiother Oncol; 2003 Aug; 68(2):105-11. PubMed ID: 12972304
[TBL] [Abstract][Full Text] [Related]
34. Management of stage II (T2N0M0) glottic carcinoma by radiotherapy and conservation surgery.
Spector JG; Sessions DG; Chao KS; Hanson JM; Simpson JR; Perez CA
Head Neck; 1999 Mar; 21(2):116-23. PubMed ID: 10091979
[TBL] [Abstract][Full Text] [Related]
35. Do overall treatment time, field size, and treatment energy influence local control of T1-T2 squamous cell carcinomas of the glottic larynx?
Fein DA; Lee WR; Hanlon AL; Ridge JA; Curran WJ; Coia LR
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):823-31. PubMed ID: 8598359
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer.
Karasawa K; Kunogi H; Hirai T; Hoji H; Hirowatari H; Izawa H; Ito K; Sasai K; Furuya T; Ozawa S; Matsumoto F; Ito S; Oba S
J Radiat Res; 2013 Jul; 54(4):684-9. PubMed ID: 23297315
[TBL] [Abstract][Full Text] [Related]
37. Comparison of early glottic and supraglottic carcinoma treated with conventional fractionation of radiotherapy.
Inoue T; Inoue T; Ikeda H; Teshima T; Yamazaki H; Murayama S; Othani M; Ozeki S
Strahlenther Onkol; 1993 Oct; 169(10):584-9. PubMed ID: 8235982
[TBL] [Abstract][Full Text] [Related]
38. Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index.
Sakata K; Oouchi A; Nagakura H; Akiba H; Tamakawa M; Koito K; Hareyama M; Asakura K; Satoh M; Ohtani S
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):81-8. PubMed ID: 10758308
[TBL] [Abstract][Full Text] [Related]
39. Transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma: a systematic review of local control outcomes.
Warner L; Lee K; Homer JJ
Clin Otolaryngol; 2017 Jun; 42(3):629-636. PubMed ID: 27863075
[TBL] [Abstract][Full Text] [Related]
40. Hypofractionated radiotherapy versus conventional radiotherapy in early glottic cancer T1-2N0M0: A randomized study.
Kachhwaha A; Jakhar SL; Syiem T; Sharma N; Kumar HS; Sharma A
J Cancer Res Ther; 2021; 17(6):1499-1502. PubMed ID: 34916384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
